Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)

Abstract

The EXPLORER study was designed to assess the response to rituximab versus placebo in patients with moderate to severe extrarenal systemic lupus erythematosus (SLE) receiving background immunosuppression. The definition of response required reduced clinical activity without subsequent flares over 52 weeks, and the study did not meet its efficacy endpoint. The current exploratory analysis assessed flare rates in patients who achieved initial low disease activity response (British Isles Lupus Assessment Group [BILAG] C or better in all organs) during the study. Exploratory reanalysis of data from the EXPLORER trial was conducted, considering alternative definitions for flare. No difference was found between rituximab and placebo in preventing or delaying moderate to severe flares. However, when severe (BILAG A) flares alone were examined, rituximab reduced the risk of a subsequent first A flare (hazard ratio = 0.61; p = 0.052) and lowered mean ± SD annualized A flare rates (0.86 ± 1.47 vs. 1.41 ± 2.14; p = 0.038). Eighty-four (49.7%) rituximab-treated patients achieved low disease activity without subsequent A flares versus 31 (35.2%) placebo-treated patients (p = 0.027). Prednisone rescue for A flares was similar in rituximab- (24%) and placebo-treated (14%) patients (p = 0.204). This post hoc analysis evaluates the hypothesis that assessment of BILAG A flares may distinguish potential treatment effects with greater sensitivity than assessment of BILAG B flares.

Keywords

BILAG flare assessment lupus flares rituximab SLE flares rituximab-treated SLE

Get full access to this article

View all access options for this article.

References

D’Cruz

. Systemic lupus erythematosus. BMJ 2006; 332: 890–894.

Renaudineau

Pers

Bendaoud

Jamin

Youinou

. Dysfunctional B cells in systemic lupus erythematosus. Autoimmun Rev 2004; 3: 516–223.

Hostmann

Jacobi

Mei

Hiepe

Dorner

. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus 2008; 17: 1064–1069.

Leandro

de la Torre

. Translational Mini-Review Series on B Cell-Directed Therapies: the pathogenic role of B cells in autoantibody-associated autoimmune diseases – lessons from B cell-depletion therapy. Clin Exp Immunol 2009; 157: 191–197.

Rituxan® (rituximab) (prescribing information). South San Francisco, CA: Genentech, Inc; 2008.

Looney

Anolik

Campbell

. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580–2589.

Albert

Kahn

Stansberry

Tsai

Eisenberg

. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 3659–3659.

Leandro

Edwards

Cambridge

Ehrenstein

Isenberg

. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2773–2777.

Merrill

Neuwelt

Wallace

. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222–233.

10.

Hay

Bacon

Gordon

. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447–458.

11.

Isenberg

Gordon

. From BILAG to BLIPS – disease activity assessment in lupus past, present and future. Lupus 2000; 9: 651–654.

12.

Navarra S, Guzman R, Gallacher A, Levy RA, Li EK. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Presented at ACR/ARHP 2009 Annual Meeting, 17–21 October 2009, Philadelphia, PA. Abstract LB1.

13.

Petri

Buyon

Kim

. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 685–691.

14.

Gordon

Sutcliffe

Skan

Stoll

Isenberg

. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003; 42: 1372–1379.

15.

Petri

Singh

Tesfasyone

Malik

. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 2009; 36: 2476–2480.